PHAS News and Press, PhaseBio Pharmaceuticals Inc.

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: f11photo/Shutterstock.com We’re starting off the day with an overview of the biggest pre-market stock movers on Tuesday! We’ve got a bankruptcy filing, earnings reports, a reverse stock split, ...

PhaseBio Pharmaceuticals ( NASDAQ: PHAS ), a biotech focused on cardiovascular diseases, dropped ~9% pre-market Monday after the company announced plans for Chapter 11 bankruptcy and a non-binding agreement to sell its leading program, bentracimab. The voluntary petiti...

Bidding Process and Auction Projected to Conclude December 2022 PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiovascular diseases, today announced that...

PhaseBio Pharmaceuticals ( NASDAQ: PHAS ) stock slumped 67.1% to $0.25 in Wednesday mid-day trading, after the company disclosed that it had received a notice from collaboration partner SFJ Pharmaceuticals for the transfer of its lead drug bentracimab's business. PHAS in Jan...

PhaseBio Pharmaceuticals press release ( NASDAQ: PHAS ): Q2 GAAP EPS of -$0.34 misses by $0.03 . Revenue of $0.21M (-98.0% Y/Y) misses by $0.29M . Shares -0.86% PM. For further details see: PhaseBio Pharmaceuticals GAAP EPS of -$0.34 misses by $0....

PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiovascular diseases, today reported financial results for the second quarter ended June 30, 2022, and provided an upd...

North Carolina-based pharma company Liquidia Corporation (NASDAQ:LQDA) lost sharply on Monday after the FDA announced the approval of a rival lung disease therapy developed by United Therapeutics (UTHR) and its partner MannKind (MNKD). Rejecting a Citizen Petition filed against its marketing ...

The clinical-stage biotech PhaseBio Pharmaceuticals (NASDAQ:PHAS) announced on Monday its plans to submit the U.S. marketing application for the company’s experimental clotting agent bentracimab in 4Q 2022. Following a Pre-BLA Meeting conducted in early April, the company has received ...

PhaseBio Pharmaceuticals press release (NASDAQ:PHAS): Q1 GAAP EPS of -$0.23 beats by $0.43. Cash and cash equivalents on March 31, 2022, were $18.7 million, compared to $41.8 million at December 31, 2021. Shares +9.52% PM. For further details see: PhaseBio Pharmaceuticals GAAP EPS of -$...

Held successful Type B pre-biologics license application (BLA) meeting with U.S. FDA for future submission of BLA for bentracimab BLA submission for bentracimab is planned for early in the fourth quarter of 2022 and PhaseBio is preparing for commercialization in U.S., if appro...